Back to Search
Start Over
Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
- Source :
- Clinical Cancer Research, 24(12), 2794-2803. American Association for Cancer Research Inc., Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (12), pp.2794-2803. ⟨10.1158/1078-0432.CCR-17-3622⟩, Clinical Cancer Research, 2018, 24 (12), pp.2794-2803. ⟨10.1158/1078-0432.CCR-17-3622⟩, Clinical Cancer Research, 24(12), 2794-2803. AMER ASSOC CANCER RESEARCH, Baron, F, Labopin, M, Ruggeri, A, Cornelissen, J J, Meijer, E, Sengeloev, H, Niederwieser, D, de Groot, M R, Schouten, H C, Milpied, N, Blaise, D, Savani, B N, Gluckman, E, Mohty, M & Nagler, A 2018, ' Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen ', Clinical Cancer Research, vol. 24, no. 12, pp. 2794-2803 . https://doi.org/10.1158/1078-0432.CCR-17-3622
- Publication Year :
- 2018
-
Abstract
- Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen. Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey. Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002). Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794–803. ©2018 AACR.
- Subjects :
- Male
Oncology
Cancer Research
UNRELATED DONOR
Transplantation Conditioning
Myeloid
[SDV]Life Sciences [q-bio]
Graft vs Host Disease
HEMATOLOGIC MALIGNANCIES
0302 clinical medicine
Recurrence
TOTAL-BODY IRRADIATION
VERSUS-HOST-DISEASE
Medicine
Registries
Incidence (epidemiology)
Hematopoietic Stem Cell Transplantation
MATCHED SIBLING DONORS
1ST COMPLETE REMISSION
Middle Aged
Total body irradiation
3. Good health
Leukemia, Myeloid, Acute
Leukemia
medicine.anatomical_structure
030220 oncology & carcinogenesis
Female
Whole-Body Irradiation
Adult
medicine.medical_specialty
Adolescent
ACUTE MYELOID-LEUKEMIA
Young Adult
03 medical and health sciences
Internal medicine
Humans
Transplantation, Homologous
Aged
Retrospective Studies
CORD-BLOOD TRANSPLANTATION
business.industry
Retrospective cohort study
medicine.disease
RELAPSE-FREE SURVIVAL
BONE-MARROW-TRANSPLANTATION
Transplantation
Regimen
business
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 10780432 and 15573265
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research, 24(12), 2794-2803. American Association for Cancer Research Inc., Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (12), pp.2794-2803. ⟨10.1158/1078-0432.CCR-17-3622⟩, Clinical Cancer Research, 2018, 24 (12), pp.2794-2803. ⟨10.1158/1078-0432.CCR-17-3622⟩, Clinical Cancer Research, 24(12), 2794-2803. AMER ASSOC CANCER RESEARCH, Baron, F, Labopin, M, Ruggeri, A, Cornelissen, J J, Meijer, E, Sengeloev, H, Niederwieser, D, de Groot, M R, Schouten, H C, Milpied, N, Blaise, D, Savani, B N, Gluckman, E, Mohty, M & Nagler, A 2018, ' Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen ', Clinical Cancer Research, vol. 24, no. 12, pp. 2794-2803 . https://doi.org/10.1158/1078-0432.CCR-17-3622
- Accession number :
- edsair.doi.dedup.....d965e629e9473d3d5694812dd443df46